BIO-TECHNE Corp Tax Withholding Paid on Stock Awards
BIO-TECHNE Corp (TECH) reported Tax Withholding Paid on Stock Awards of $12.14 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-24
- BIO-TECHNE Corp payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $1.50M, a 540.17% increase year-over-year.
- BIO-TECHNE Corp payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $157.00K, a 46.05% decline year-over-year.
- BIO-TECHNE Corp payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $1.25M, a 23.89% increase year-over-year.
- BIO-TECHNE Corp payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $9.23M, a 85.21% increase year-over-year.
- BIO-TECHNE Corp payment, tax withholding, share-based payment arrangement for fiscal 2026 was $12.14M, a 86.15% increase from fiscal 2025.
- BIO-TECHNE Corp payment, tax withholding, share-based payment arrangement for fiscal 2025 was $6.52M, a 70.18% decline from fiscal 2024.
- BIO-TECHNE Corp payment, tax withholding, share-based payment arrangement for fiscal 2024 was $21.87M, a 24.30% decline from fiscal 2023.
- BIO-TECHNE Corp payment, tax withholding, share-based payment arrangement for fiscal 2023 was $28.89M, a 23.15% increase from fiscal 2022.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $1.66M derived: sum of 2 quarters · filed 2026-08-24 | $2.91M derived: sum of 3 quarters · filed 2026-08-24 | $12.14M 10-K · filed 2026-08-24 |
| 2026-03-31 | $157.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $1.41M derived: sum of 2 quarters · filed 2026-05-06 | $10.64M 10-Q · filed 2026-05-06 | $10.88M derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-12-31 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-04 | $10.49M 10-Q · filed 2026-02-04 | $10.72M derived: sum of 3 quarters · filed 2026-08-24 | $11.01M derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-09-30 | $9.23M 10-Q · filed 2025-11-05 | $9.46M derived: sum of 2 quarters · filed 2026-08-24 | $9.76M derived: sum of 3 quarters · filed 2026-08-24 | $10.77M derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-06-30 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $525.00K derived: sum of 2 quarters · filed 2026-08-24 | $1.54M derived: sum of 3 quarters · filed 2026-08-24 | $6.52M 10-K · filed 2026-08-24 |
| 2025-03-31 | $291.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $1.30M derived: sum of 2 quarters · filed 2026-05-06 | $6.29M 10-Q · filed 2026-05-06 | $6.69M derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-12-31 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-04 | $6.00M 10-Q · filed 2026-02-04 | $6.40M derived: sum of 3 quarters · filed 2026-08-24 | $6.57M derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-09-30 | $4.98M 10-Q · filed 2025-11-05 | $5.39M derived: sum of 2 quarters · filed 2026-08-24 | $5.55M derived: sum of 3 quarters · filed 2026-08-24 | $6.63M derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-06-30 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $570.00K derived: sum of 2 quarters · filed 2026-08-24 | $1.64M derived: sum of 3 quarters · filed 2026-08-24 | $21.87M 10-K · filed 2026-08-24 |
| 2024-03-31 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-08 | $1.24M derived: sum of 2 quarters · filed 2025-05-08 | $21.47M 10-Q · filed 2025-05-08 | $21.51M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-12-31 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-06 | $21.30M 10-Q · filed 2025-02-06 | $21.34M derived: sum of 3 quarters · filed 2025-08-22 | $32.34M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-09-30 | $20.23M 10-Q · filed 2024-11-05 | $20.27M derived: sum of 2 quarters · filed 2025-08-22 | $31.27M derived: sum of 3 quarters · filed 2025-08-22 | $31.27M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-06-30 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $11.04M derived: sum of 2 quarters · filed 2025-08-22 | $11.04M derived: sum of 3 quarters · filed 2025-08-22 | $28.89M 10-K · filed 2025-08-22 |
| 2023-03-31 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-06 | $11.00M derived: sum of 2 quarters · filed 2024-05-06 | $28.85M 10-Q · filed 2024-05-06 | $28.91M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-07 | $17.85M 10-Q · filed 2024-02-07 | $17.91M derived: sum of 3 quarters · filed 2024-08-22 | $18.07M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-09-30 | $17.85M 10-Q · filed 2023-11-07 | $17.91M derived: sum of 2 quarters · filed 2024-08-22 | $18.07M derived: sum of 3 quarters · filed 2024-08-22 | $18.07M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-06-30 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | $214.00K derived: sum of 2 quarters · filed 2024-08-22 | $215.00K derived: sum of 3 quarters · filed 2024-08-22 | $23.46M 10-K · filed 2024-08-22 |
| 2022-03-31 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-08 | $160.00K derived: sum of 2 quarters · filed 2023-05-08 | $23.41M 10-Q · filed 2023-05-08 | |
| 2021-12-31 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-07 | $23.25M 10-Q · filed 2023-02-07 | ||
| 2021-09-30 | $23.25M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $19.34M 10-K · filed 2023-08-23 | |||
| 2020-06-30 | $3.87M 10-K · filed 2022-08-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |